BMRN Stock: Price, Earnings History and SEC Filings
BioMarin Pharmaceutical Inc. (BMRN) last traded at $58.51, up 1.77% on the latest session and down 2.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.90 against an analyst estimate of $0.79, a beat of 13.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BMRN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.90 | $0.79 | +13.92% |
| Mar 2026 | May 4, 2026 | $0.58 | $0.78 | -25.64% |
| Dec 2025 | Feb 23, 2026 | $0.28 | $0.07 | +300.00% |
| Sep 2025 | Oct 27, 2025 | $-0.08 | $0.82 | -109.76% |
BMRN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How BMRN reacts to earnings
Across its last 8 earnings releases, BMRN moved 2.1% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-06 | After close | -1.81% |
| 2026-08-06 | After close | +3.82% |
| 2026-05-04 | After close | -4.00% |
| 2026-02-23 | After close | -0.48% |
| 2026-01-26 | Before open | +1.01% |
| 2026-01-12 | After close | -4.35% |
| 2025-10-27 | After close | +1.56% |
| 2025-10-07 | After close | -0.02% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BMRN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $3.2B | $349M | $725M | 10.8% | $1.80 |
| 2024 | $2.9B | $427M | $487M | 15.0% | $2.21 |
| 2023 | $2.4B | $168M | $63M | 6.9% | $0.87 |
| 2022 | $2.1B | $142M | $55M | 6.8% | $0.75 |
| 2021 | $1.8B | -$64M | $209M | -3.5% | $-0.35 |
| 2020 | $1.9B | $854M | -$29M | 45.9% | $4.50 |
| 2019 | $1.7B | -$24M | -$97M | -1.4% | $-0.13 |
| 2018 | $1.5B | -$77M | -$124M | -5.2% | $-0.44 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BMRN
- 8-K · Oct 6, 2026Results of operations
- 8-K · Sep 30, 2026Material agreement
- 8-K · Sep 15, 2026Other events
- 8-K · Sep 14, 2026Officer or director change
- 8-K · Sep 1, 2026Other events
- 8-K · Aug 31, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 18, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Officer or director change, Shareholder vote
Insider filing activity
BMRN insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BMRN news
- BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expectNov 1, 2026 · finance.yahoo.com
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?Oct 31, 2026 · finance.yahoo.com
- Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In DealmakingOct 31, 2026 · stocktwits.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry DiseaseOct 29, 2026 · finance.yahoo.com
- What Would Slower New Drug Sales Do To Vertex Stock?Oct 28, 2026 · trefis.com
- BioMarin schedules third-quarter results. BioMarin stock is valued at USD 10.7 billionOct 27, 2026 · ad-hoc-news.de
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.